Novo's Suit Over Compounded Weight-Loss Drug Is Tossed

By Beth JoJack · November 9, 2023, 9:09 PM EST

A Florida federal judge has issued an order dismissing Novo Nordisk Inc.'s suit against a Florida independent pharmacy for selling compounded semaglutide, a peptide also found in Ozempic, Novo's blockbuster diabetes...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Novo Nordisk Inc. v. Brooksville Pharmaceuticals Inc.

Case Number

Court

Florida Middle

Nature of Suit

Personal Property: Other

Date Filed

July 06, 2023

Recent Articles By Beth

February 14, 2024
Telehealth Advocates Press DEA On Prescription 'Red Flags'
February 13, 2024
HCA Healthcare Exec VP's Promotion Brings Expanded Duties
February 12, 2024
Pa. Judge Won't Certify Class In Juvenile Facility Abuse Suit
February 08, 2024
Drugmaker Challenges W.Va. Abortion Ban In 4th Circ.
February 07, 2024
Penn State Health To Pay $11.7M To US Over Improper Billing
February 06, 2024
AI Operating System Built For Healthcare Lands $70M
February 05, 2024
Colo. Software Co. Won't Release Patient Data, Practice Says
February 02, 2024
Dinsmore Broadens Healthcare Capabilities With New Partner
February 01, 2024
Ex-FDA Leaders Urge High Court To Nix Mifepristone Ruling
February 01, 2024
NJ Says Constitution Doesn't Protect Medical Aid In Dying